Screen Summary
Gallipoli P (2018) - 1-PMID29463564
Title: Glutaminolysis is a metabolic dependency in FLT3 acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.
Screen Details:
- Screen Type : Negative Selection | Format: Pool
- Cell Line : MOLM-13 cell | Type: Acute Myeloid Leukemia Cell Line
- Throughput : High Throughput
- Enzyme : CAS9
- Phenotype : Viability
- Experimental Setup : Drug Exposure | Duration: 30 Days | Condition Name: Quizartinib (AC220) (1.5 µg/mL)
- Library : Human Improved Genome-wide Knockout CRISPR Library | Type: CRISPRn | Methodology: Knockout
- Analysis Method : MaGeCK | Number of Hits: 302 | Full Dataset Size: 18,010
- Significance : Authors have indicated that ALL results are to be considered significant.
Notes:
- Authors screened MOLM13 cells treated with the highly potent and specific FLT3ITD inhibitor AC220 (quizartinib) for genes which resulted in synthetic lethality to identify genes and pathways that would sensitize FLT3ITD AML to FLT3-TKI treatment
Score Distribution
< -0.643674486
> -3.603478037